Towards tailored vaccine delivery: Needs, challenges and perspectives

被引：80
作者：
Amorij, Jean-Pierre [2 ]
Kersten, Gideon F. A. [2 ]
Saluja, Vinay [2 ]
Tonnis, Wouter F. [3 ]
Hinrichs, Wouter L. J. [3 ]
Slutter, Bram [4 ]
Bal, Suzanne M. [5 ]
Bouwstra, Joke A. [1 ]
Huckriede, Anke [6 ,7 ]
Jiskoot, Wim [1 ]
机构：
[1] Leiden Univ, LACDR, Div Drug Delivery Technol, NL-2333 CC Leiden, Netherlands
[2] Natl Inst Publ Hlth & Environm, NL-3720 BA Bilthoven, Netherlands
[3] Univ Groningen RuG, Dept Pharmaceut Technol & Biopharm, Groningen, Netherlands
[4] Univ Iowa, Dept Microbiol, Iowa City, IA 52242 USA
[5] Univ Amsterdam, Acad Med Ctr, Dept Resp Med, Div Expt Immunol, NL-1105 AZ Amsterdam, Netherlands
[6] Univ Med Ctr Groningen, Mol Virol Sect, Dept Med Microbiol, NL-9713 AV Groningen, Netherlands
[7] Univ Groningen, Groningen, Netherlands
来源：
JOURNAL OF CONTROLLED RELEASE | 2012年 / 161卷 / 02期
关键词：
Adjuvant; Device; Formulation; Mucosal vaccination; Targeting; Transcutaneous vaccination; INFLUENZA SUBUNIT VACCINE; T-CELL RESPONSES; RESPIRATORY SYNCYTIAL VIRUS; TOLL-LIKE RECEPTORS; RECOMBINANT PROTEIN VACCINE; MEDIATED IMMUNE-RESPONSES; PHASE-I TRIAL; PLASMODIUM-FALCIPARUM; MALARIA VACCINE; DENDRITIC CELLS;
D O I：
10.1016/j.jconrel.2011.12.039
中图分类号：
O6 [化学];
学科分类号：
0703 ;
摘要：
The ideal vaccine is a simple and stable formulation which can be conveniently administered and provides life-long immunity against a given pathogen. The development of such a vaccine, which should trigger broad and strong B-cell and T-cell responses against antigens of the pathogen in question, is highly dependent on tailored vaccine delivery approaches. This review addresses vaccine delivery in its broadest scope. We discuss the needs and challenges in the area of vaccine delivery, including restrictions posed by specific target populations, potentials of dedicated stable formulations and devices, and the use of adjuvants. Moreover, we address the current status and perspectives of vaccine delivery via several routes of administration, including non-or minimally invasive routes. Finally we suggest possible directions for future vaccine delivery research and development. (C) 2012 Elsevier B.V. All rights reserved.
引用
收藏
页码：363 / 376
页数：14
相关论文
共 191 条
  • [1] Immunization of malignant melanoma patients with full-length NY-ESO-1 protein using TLR7 agonist imiquimod as vaccine adjuvant
    Adams, Sylvia
    O'Neill, David W.
    Nonaka, Daisuke
    Hardin, Elizabeth
    Chiriboga, Luis
    Siu, Kimberly
    Cruz, Crystal M.
    Angiulli, Angelica
    Angiulli, Francesca
    Ritter, Erika
    Holman, Rose Marie
    Shapiro, Richard L.
    Berman, Russell S.
    Berner, Natalie
    Shao, Yongzhao
    Manches, Olivier
    Pan, Linda
    Venhaus, Ralph R.
    Hoffman, Eric W.
    Jungbluth, Achim
    Gnjatic, Sacha
    Old, Lloyd
    Pavlick, Anna C.
    Bhardwaj, Nina
    [J]. JOURNAL OF IMMUNOLOGY, 2008, 181 (01) : 776 - 784
  • [2] Long-Term Thermostabilization of Live Poxviral and Adenoviral Vaccine Vectors at Supraphysiological Temperatures in Carbohydrate Glass
    Alcock, Robert
    Cottingham, Matthew G.
    Rollier, Christine S.
    Furze, Julie
    De Costa, Samodh D.
    Hanlon, Marian
    Spencer, Alexandra J.
    Honeycutt, Jared D.
    Wyllie, David H.
    Gilbert, Sarah C.
    Bregu, Migena
    Hill, Adrian V. S.
    [J]. SCIENCE TRANSLATIONAL MEDICINE, 2010, 2 (19) : 19ra12
  • [3] Efficacy of the RTS,S/AS02A vaccine against Plasmodium falciparum infection and disease in young African children:: randomised controlled trial
    Alonso, PL
    Sacarlal, J
    Aponte, JJ
    Leach, A
    Macete, E
    Milman, J
    Mandomando, I
    Spiessens, B
    Guinovart, C
    Espasa, M
    Bassat, Q
    Aide, P
    Ofori-Anyinam, O
    Navia, MM
    Corachan, S
    Ceuppens, M
    Dubois, MC
    Demoitié, MA
    Dubovsky, F
    Menéndez, C
    Tornieporth, N
    Ballou, WR
    Thompson, R
    Cohen, J
    [J]. LANCET, 2004, 364 (9443) : 1411 - 1420
  • [4] Ambrose CS, 2008, INFLUENZA OTHER RESP, V2, P193, DOI 10.1111/j.1750-2659.2008.00056.x
  • [5] Rational design of an influenza subunit vaccine powder with sugar glass technology: Preventing conformational changes of haemagglutinin during freezing and freeze-drying
    Amorij, J.-P.
    Meulenaar, J.
    Hinrichs, W. L. J.
    Stegmann, T.
    Huckriede, A.
    Coenen, F.
    Frijlink, H. W.
    [J]. VACCINE, 2007, 25 (35) : 6447 - 6457
  • [6] Development of stable influenza vaccine powder formulations: Challenges and possibilities
    Amorij, J-P.
    Huckriede, A.
    Wischut, J.
    Frijlink, H. W.
    Hinrichs, W. L. J.
    [J]. PHARMACEUTICAL RESEARCH, 2008, 25 (06) : 1256 - 1273
  • [7] Towards an oral influenza vaccine: Comparison between intragastric and intracolonic delivery of influenza subunit vaccine in a murine model
    Amorij, J-P.
    Westra, T. A.
    Hinrichs, W. L. J.
    Huckriede, A.
    Frijlink, H. W.
    [J]. VACCINE, 2007, 26 (01) : 67 - 76
  • [8] Pulmonary delivery of an inulin-stabilized influenza subunit vaccine prepared by spray-freeze drying induces systemic, mucosal humoral as well as cell-mediated immune responses in BALB/c mice
    Amorij, J-P.
    Saluja, V.
    Petersen, A. H.
    Hinrichs, W. L. J.
    Huckriede, A.
    Frijlink, H. W.
    [J]. VACCINE, 2007, 25 (52) : 8707 - 8717
  • [9] [Anonymous], 2009, MORBIDITY MORTALITY
  • [10] New generation vaccine induces effective melanoma-specific CD8+ T cells in the circulation but not in the tumor site
    Appay, Victor
    Jandus, Camilla
    Voelter, Verena
    Reynard, Severine
    Coupland, Sarah E.
    Rimoldi, Donata
    Lienard, Danielle
    Guillaume, Philippe
    Krieg, Arthur M.
    Cerottini, Jean-Charles
    Romero, Pedro
    Leyvraz, Serge
    Rufer, Nathalie
    Speiser, Daniel E.
    [J]. JOURNAL OF IMMUNOLOGY, 2006, 177 (03) : 1670 - 1678
12345678910